Rani Therapeutics Holdings (RANI) Current Assets (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Current Assets of $47.1 million for Q1 2026, up 164.81% year-over-year from $17.8 million in Q1 2025, and down 11.68% quarter-over-quarter from $53.3 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Current Assets (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Current Assets history runs 7 years deep, the most recent figure standing at $47.1 million for Q1 2026.
- In Q1 2026, Current Assets rose 164.81% year-over-year to $47.1 million; the TTM figure through Mar 2026 stood at $47.1 million (up 164.81% YoY), while the FY2025 annual figure was $53.3 million, up 79.27% from the prior year.
- Current Assets for Q1 2026 stood at $47.1 million, down from $53.3 million in the prior quarter.
- The five-year high for Current Assets was $109.3 million in Q1 2022, with the low at $5.0 million in Q3 2025.
- The 5-year median for Current Assets is $50.8 million (2023), against an average of $56.4 million.
- The sharpest annual moves came in 2025 and 2026: Current Assets slumped 84.69% in 2025, then soared 164.81% in 2026.
- Rani Therapeutics Holdings' Current Assets stood at $100.9 million in 2022, then tumbled by 49.62% to $50.8 million in 2023, then sank by 41.5% to $29.7 million in 2024, then jumped by 79.27% to $53.3 million in 2025, then slipped by 11.68% to $47.1 million in 2026.
- Business Quant data shows RANI's Current Assets at $47.1 million in Q1 2026, $53.3 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | 56.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.52 Mn |
| Mar 31, 2026 | 47.09 Mn |
| Dec 31, 2025 | 53.32 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | 11.07 Mn |
| Mar 31, 2025 | 17.78 Mn |
| Dec 31, 2024 | 29.74 Mn |
| Sep 30, 2024 | 32.37 Mn |
| Jun 30, 2024 | 32.03 Mn |
| Mar 31, 2024 | 41.39 Mn |
| Dec 31, 2023 | 50.85 Mn |
| Sep 30, 2023 | 63.22 Mn |
| Jun 30, 2023 | 76.37 Mn |
| Mar 31, 2023 | 89.04 Mn |
| Dec 31, 2022 | 100.92 Mn |
| Sep 30, 2022 | 100.72 Mn |
| Jun 30, 2022 | 97.99 Mn |
| Mar 31, 2022 | 109.26 Mn |
| Dec 31, 2021 | 119.60 Mn |
| Sep 30, 2021 | 132.37 Mn |